

WY P&T Committee Meeting Minutes  
Thursday, May 14, 2015  
Cheyenne, WY  
10 a.m – 1 p.m.

Members present: Andrew Beaulieu, Joe Horam, Rhonda McLaughlin, Robert Monger, Garry Needham, Scot Schmidt, David Sy, Dean Winsch, Tonja Woods, Pat Yost

Excused: Brent Sherard

Ex-officio: Melissa Hunter, Cori Cooper, Donna Artery

Guests: Sara Howe (GHS), Amy Stockton (GHS), Nikki Yost (GHS), Steve Liles (GHS), Wendy Rockwell (AstraZeneca), Caroline Kicklighter (Novartis), Bradley Haas (AstraZeneca), Rob Coppola (Magellan Medicaid Administration), Christine Olds (Takeda), Carole H. (Pfizer), Mark German (Novartis), Cassandra Johnson (Alkermes), Jim McKay (Sandoz), Michele Poyear (Gilead)

Dr. Monger called the meeting to order at 10:00 a.m.

Introductions were made.

Aimee announced the resignation of Dr. Stephen Brown from the P&T Committee due to conflicts with other commitments.

Approval of Minutes

The minutes of the February 18, 2015 meeting were approved as submitted.

Department of Health

A. Pharmacy Program Manager Report: Brenda Stout received her Bachelor's Degree in Psychology and accepted a new position as the Behavioral Health Program Manager for the Department of Health. The RFP for PBM services will be released before the middle of June. The current contract ends June 30, 2016. CMS denied the medication therapy management contract amendment based on the timing with the current RFP process.

B. Medical Director Report: The Patient Centered Medical Home project is operational. Four practices are enrolled, submitting data and being paid. Twenty-nine practices are currently eligible. Dr. Horam indicated that Blue Cross is looking at implementing a similar program.

C. DUR Manager Report: Aimee had nothing new to report.

Old Business

Duplicate antidepressant utilization and the request to allow use of Cymbalta and Viibryd together was tabled for the closed session.

### New Business

A. Steve Liles gave a presentation on the biosimilar approval process. Biologics are currently approximately 1% of the number of prescriptions and account for 25 to 30% of the drug spend. It is expected to increase by 6% annually.

#### B. PA Criteria

##### 1. Review existing PA criteria:

i. A recommendation was made that the prior authorization criteria for Hepatitis C include a test for Hepatitis B to be conducted no more than 30 days prior to the prior authorization request. There was a motion, second and all were in favor of amending the prior authorization to include a Hepatitis B test.

ii. Per discussion at the February meeting, a legal form was developed from a similar form used in DC. This form requires the Hepatitis C patient to acknowledge that they understand their prescribed treatment and that Medicaid will only pay for treatment one time. There was a motion, second and all were in favor of including this form with the Hepatitis C prior authorization form.

##### 3. New Drugs

i. Mircera is a pegylated epoetin, returning to the market. The Committee agreed that the safety and efficacy of this medication is similar to existing drugs in the class. The Department of Health will complete a cost analysis to determine placement of this medication.

ii. Movantik is pegylated naloxone which selectively binds to mu receptors in the periphery, reducing opioid-induced constipation. Public comment was provided by Bradley Haas (Astra Zeneca). The Committee asked why this drug was not approved in cancer patients. Mr. Haas indicated that the cancer study was discontinued due to poor enrollment.

The other drugs for this indication are Amitiza and Relistor. There was a motion, second and all were in favor of requiring the diagnosis of opioid-induced constipation and a three month trial of a secretory agent prior to approval of these drugs.

iii. Cosentyx is a new interleukin-17 cytokine approved for plaque psoriasis. Caroline Kicklighter (Novartis) provided public comment. Cosentyx showed superiority over Enbrel for plaque psoriasis. There is no head to head data vs. Humira. It has not shown efficacy in rheumatoid arthritis, however they are looking into ankylosing spondylitis and psoriatic arthritis. The Committee agreed that there is evidence of a safety and efficacy advantage over Enbrel for plaque psoriasis. There was a motion, second and all were in favor of this recommendation. The Department of Health will conduct a cost analysis to determine placement on the PDL.

iv. Cholbam is a bile acid, approved for a rare genetic enzyme disorder. There was a motion, second and all were in favor of limiting the drug to its approved indication.

C. Other: None

There being no further business, the open portion of the meeting adjourned at 11:32 a.m.

The utilization of duplicate antidepressants was reviewed and discussed during the closed session. It was determined that use of two or more antidepressants concurrently with little clinical rationale was occurring and should be managed. Prior authorization will be required for concurrent use. Exceptions to this rule will include trazodone, tricyclic antidepressants and SSRIs with bupropion or mirtazapine. There was a motion, second and all were in favor of this criteria.

Aimee Lewis  
WYDUR Manager